Metagenomi (MGX) Competitors $1.85 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.87 +0.02 (+1.08%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. MRNA, AVIR, MREO, LFCR, DBVT, EDIT, VOR, ANNX, NMRA, and ALMSShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), Atea Pharmaceuticals (AVIR), Mereo BioPharma Group (MREO), Lifecore Biomedical (LFCR), DBV Technologies (DBVT), Editas Medicine (EDIT), Vor Biopharma (VOR), Annexon (ANNX), Neumora Therapeutics (NMRA), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Its Competitors Moderna Atea Pharmaceuticals Mereo BioPharma Group Lifecore Biomedical DBV Technologies Editas Medicine Vor Biopharma Annexon Neumora Therapeutics Alumis Metagenomi (NASDAQ:MGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do analysts rate MGX or MRNA? Metagenomi currently has a consensus target price of $10.00, indicating a potential upside of 440.54%. Moderna has a consensus target price of $43.59, indicating a potential upside of 66.24%. Given Metagenomi's stronger consensus rating and higher probable upside, equities analysts plainly believe Metagenomi is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Which has more risk and volatility, MGX or MRNA? Metagenomi has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Do insiders and institutionals have more ownership in MGX or MRNA? 75.3% of Moderna shares are held by institutional investors. 17.8% of Metagenomi shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is MGX or MRNA more profitable? Moderna has a net margin of -94.31% compared to Metagenomi's net margin of -257.99%. Moderna's return on equity of -25.96% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-257.99% -37.84% -27.15% Moderna -94.31%-25.96%-20.09% Does the media prefer MGX or MRNA? In the previous week, Metagenomi had 6 more articles in the media than Moderna. MarketBeat recorded 22 mentions for Metagenomi and 16 mentions for Moderna. Moderna's average media sentiment score of 0.40 beat Metagenomi's score of -0.20 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Which has preferable valuation & earnings, MGX or MRNA? Metagenomi has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.29M1.33-$78.06M-$2.36-0.78Moderna$3.24B3.15-$3.56B-$7.53-3.48 SummaryModerna beats Metagenomi on 9 of the 16 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.43M$2.49B$5.74B$9.56BDividend YieldN/A1.66%4.53%4.08%P/E Ratio-0.7822.4830.4525.16Price / Sales1.33549.05392.5887.64Price / CashN/A173.7937.0358.50Price / Book0.355.268.956.21Net Income-$78.06M$31.83M$3.26B$265.38M7 Day Performance-2.63%0.83%1.06%-1.13%1 Month Performance-14.75%3.71%4.31%-0.71%1 Year Performance-44.28%9.37%28.40%18.89% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi2.2357 of 5 stars$1.85flat$10.00+440.5%-43.9%$69.43M$52.29M-0.78236Trending NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.3827 of 5 stars$28.09+0.2%$43.59+55.2%-69.1%$10.90B$3.24B-3.735,800AVIRAtea Pharmaceuticals1.7722 of 5 stars$3.53+0.9%$6.00+70.0%-7.9%$277.75MN/A-2.1970MREOMereo BioPharma Group2.2831 of 5 stars$1.68-3.4%$7.20+328.6%-63.3%$276.66M$10M-24.0040LFCRLifecore Biomedical1.433 of 5 stars$7.40+0.4%$8.00+8.1%+27.2%$275.70M$128.87M-5.65690News CoverageDBVTDBV Technologies3.3198 of 5 stars$10.00+0.1%$14.75+47.5%+117.0%$273.62M$4.15M-2.1080Gap UpHigh Trading VolumeEDITEditas Medicine4.2094 of 5 stars$2.73-9.9%$5.10+86.8%-32.6%$272.46M$32.31M-0.96230VORVor Biopharma0.463 of 5 stars$2.04-4.7%N/AN/A$271.10MN/A-0.15140Short Interest ↑ANNXAnnexon2.8989 of 5 stars$2.35-3.7%$12.50+431.9%-64.3%$267.70MN/A-1.8260Earnings ReportAnalyst UpgradeNMRANeumora Therapeutics2.6178 of 5 stars$1.64+0.6%$7.14+335.5%-86.4%$263.97MN/A-1.04108ALMSAlumis2.9997 of 5 stars$4.85+2.1%$20.17+315.8%-66.1%$258.43MN/A0.00N/AAnalyst Revision Related Companies and Tools Related Companies Moderna Competitors Atea Pharmaceuticals Competitors Mereo BioPharma Group Competitors Lifecore Biomedical Competitors DBV Technologies Competitors Editas Medicine Competitors Vor Biopharma Competitors Annexon Competitors Neumora Therapeutics Competitors Alumis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access